Carroll Financial Associates’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | $173K | Sell |
1,492
-11
| -0.7% | -$1.29K | 0.01% | 417 |
|
|
2021
Q3 | $180K | Buy |
1,503
+32
| +2% | +$3.73K | 0.01% | 414 |
|
|
2021
Q2 | $176K | Buy |
1,471
+41
| +3% | +$4.5K | 0.01% | 440 |
|
|
2021
Q1 | $142K | Buy |
1,430
+23
| +2% | +$2.31K | 0.01% | 480 |
|
|
2020
Q4 | $140K | Hold |
1,407
| – | – | 0.01% | 447 |
|
|
2020
Q3 | $154K | Sell |
1,407
-341
| -20% | -$37.9K | 0.01% | 382 |
|
|
2020
Q2 | $184K | Buy |
1,748
+320
| +22% | +$33K | 0.02% | 351 |
|
|
2020
Q1 | $127K | Sell |
1,428
-159
| -10% | -$15K | 0.01% | 377 |
|
|
2019
Q4 | $158K | Buy |
1,587
+17
| +1% | +$1.6K | 0.01% | 409 |
|
|
2019
Q3 | $139K | Hold |
1,570
| – | – | 0.01% | 436 |
|
|
2019
Q2 | $129K | Buy |
1,570
+359
| +30% | +$28.1K | 0.01% | 439 |
|
|
2019
Q1 | $97K | Sell |
1,211
-24
| -2% | -$1.89K | 0.01% | 455 |
|
|
2018
Q4 | $95K | Sell |
1,235
-54
| -4% | -$4.22K | 0.01% | 379 |
|
|
2018
Q3 | $102K | Buy |
1,289
+2
| +0.2% | +$151 | 0.01% | 380 |
|
|
2018
Q2 | $90K | Hold |
1,287
| – | – | 0.01% | 404 |
|
|
2018
Q1 | $89K | Buy |
1,287
+1,000
| +348% | +$69.3K | 0.01% | 401 |
|
|
2017
Q4 | $19K | Hold |
287
| – | – | ﹤0.01% | 666 |
|
|
2017
Q3 | $19K | Buy |
287
+27
| +10% | +$1.71K | ﹤0.01% | 666 |
|
|
2017
Q2 | $17K | Hold |
260
| – | – | ﹤0.01% | 714 |
|
|
2017
Q1 | $16K | Hold |
260
| – | – | ﹤0.01% | 711 |
|
|
2016
Q4 | $14K | Sell |
260
-68
| -21% | -$3.86K | ﹤0.01% | 711 |
|
|
2016
Q3 | $21K | Buy |
328
+117
| +55% | +$7.65K | ﹤0.01% | 637 |
|
|
2016
Q2 | $12K | Buy |
211
+124
| +143% | +$7.2K | ﹤0.01% | 739 |
|
|
2016
Q1 | $4K | Sell |
87
-50
| -36% | -$3K | ﹤0.01% | 929 |
|
|
2015
Q4 | $9K | Buy |
137
+50
| +57% | +$3.28K | ﹤0.01% | 758 |
|
|
2015
Q3 | $5K | Buy |
87
+54
| +164% | +$3.55K | ﹤0.01% | 838 |
|
|
2015
Q2 | $2K | Sell |
33
-50
| -60% | -$3.42K | ﹤0.01% | 971 |
|
|
2015
Q1 | $6K | Buy |
83
+53
| +177% | +$3.68K | ﹤0.01% | 599 |
|
|
2014
Q4 | $2K | Sell |
30
-543
| -95% | -$38.9K | ﹤0.01% | 653 |
|
|
2014
Q3 | $42K | Sell |
573
-33
| -5% | -$2.42K | 0.01% | 330 |
|
|
2014
Q2 | $45K | Hold |
606
| – | – | 0.01% | 341 |
|
|
2014
Q1 | $39K | Hold |
606
| – | – | 0.01% | 329 |
|
|
2013
Q4 | $35K | Sell |
606
-10
| -2% | -$543 | 0.01% | 331 |
|
|
2013
Q3 | $31K | Buy |
+616
| New | +$30.9K | 0.01% | 353 |
|
Other funds holding AZN
Carroll Financial Associates's AZN Position: Q4 2021 in Review
Carroll Financial Associates reduced its AstraZeneca (AZN) stake by 0.73% in Q4 2021, selling an estimated $1.29K and leaving 1,492 shares worth $173K. The position accounts for 0.01% of the portfolio, ranked #417.
Carroll Financial Associates first reported a position in AZN in Q3 2013 and has held it in 34 quarters since. The position peaked at $184K in Q2 2020. 950 funds tracked by Wall St. Rank hold AZN as of Q4 2021.
- Carroll Financial Associates held 1,492 shares of AstraZeneca worth $173K as of Q4 2021.
- Carroll Financial Associates sold 11 AstraZeneca shares in Q4 2021, an estimated $1.29K.
- AstraZeneca made up 0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #417 holding.
- Carroll Financial Associates first reported a position in AstraZeneca in Q3 2013 and has held it in 34 quarters since.
- Carroll Financial Associates's AstraZeneca position peaked at $184K in Q2 2020.
- 950 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2021.
Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.